Outi Itkonen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Outi Itkonen has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
- Ulf-Håkan Stenman
Department of Clinical Chemistry, Helsinki University Central Hospital, Helsinki, Finland
5 shared publications Esa Hämäläinen
Huslab, Helsinki University Central Hospital, Helsinki, Finland
3 shared publicationsJaakko Parkkinen
Department of Clinical Chemistry University of Helsinki Helsinki, Finland
3 shared publicationsUrsula Turpeinen
Huslab, Helsinki University Central Hospital, Helsinki, Finland
3 shared publicationsAasne K. Aarsand
Norwegian Organization for Quality Improvement of Laboratory Examinations (NOKLUS), Haraldsplass Deaconess Hospital, Bergen, Norway; Norwegian Porphyria Centre, Department of Medical Biochemistry and Pharmacology, Haukeland University Hospital, Bergen, Norway
2 shared publicationsAbdurrahman Coskun
Acibadem Mehmet Ali Aydınlar University, School of Medicine, Department of Medical Biochemistry Atasehir, Istanbul, Turkey
2 shared publications
Latest Publications
- Open Access
- 3 November 2025
- Published by Wiley in European Journal of Neurology
- Vol. 32 (11) , e70411
Optimized Kappa‐Index Test Protocol to Detect Intrathecal Immunoglobulin Synthesis in Multiple Sclerosis
Background: Kappa free light chain (KFLC)‐based Kappa‐index (K‐index) can substitute oligoclonal banding (OCB) to detect intrathecal immunoglobulin synthesis. Cutoffs for positive results vary; therefore, further comparison of different approaches is necessary to optimize K‐index for diagnostic utilization. Methods: We analyzed 432 paired CSF/serum samples and selected 77 OCB‐positive patients with multiple sclerosis (MS), clinically isolated syndrome (CIS) that did not progress to MS in > 10 years, and other neuroinflammatory diseases (non‐MS). K‐index subtests were measured on the Optilite platform (The Binding Site) and OCB with isoelectric focusing on the Hydrasys platform (Sebia). Results: OCB positive cases had a higher K‐index than OCB negative. The MS group had a higher K‐index than CIS ( p = 0.0066) and non‐MS ( p < 0.0001). A K‐index over 80.9 suggests MS over CIS, and 61.4 suggests MS over non‐MS. Different values to mimic undetectable CSF KFLC levels resulted in different cutoffs against positive OCB. Using the limit of detection (LOD) of the assay and fixing sensitivity and specificity to 95% to establish the gray area, the cutoffs were < 4.45 (negative) and > 12.92 (positive). When undetectable CSF KFLC was also considered negative, specificity against OCB was 99.7% and sensitivity 92.7%, leaving 6% for gray area OCB verification testing. Conclusions: Published K‐index cutoffs vary due to different settings of CSF KFLC results below LOD. Using a reflex approach, where samples within a certain K‐index gray area are subjected to OCB verification testing, and where samples with CSF KFLC below LOD are considered negative, was the most efficient laboratory algorithm. K‐index may also have prognostic value in MS.
- 3 November 2025
- Published by Wiley in European Journal of Neurology
- Vol. 32 (11) , e70411
Open AccessOptimized Kappa‐Index Test Protocol to Detect Intrathecal Immunoglobulin Synthesis in Multiple Sclerosis
Background: Kappa free light chain (KFLC)‐based Kappa‐index (K‐index) can substitute oligoclonal banding (OCB) to detect intrathecal immunoglobulin synthesis. Cutoffs for positive results vary; therefore, further comparison of different approaches is necessary to optimize K‐index for diagnostic utilization. Methods: We analyzed 432 paired CSF/serum samples and selected 77 OCB‐positive patients with multiple sclerosis (MS), clinically isolated syndrome (CIS) that did not progress to MS in > 10 years, and other neuroinflammatory diseases (non‐MS). K‐index subtests were measured on the Optilite platform (The Binding Site) and OCB with isoelectric focusing on the Hydrasys platform (Sebia). Results: OCB positive cases had a higher K‐index than OCB negative. The MS group had a higher K‐index than CIS ( p = 0.0066) and non‐MS ( p < 0.0001). A K‐index over 80.9 suggests MS over CIS, and 61.4 suggests MS over non‐MS. Different values to mimic undetectable CSF KFLC levels resulted in different cutoffs against positive OCB. Using the limit of detection (LOD) of the assay and fixing sensitivity and specificity to 95% to establish the gray area, the cutoffs were < 4.45 (negative) and > 12.92 (positive). When undetectable CSF KFLC was also considered negative, specificity against OCB was 99.7% and sensitivity 92.7%, leaving 6% for gray area OCB verification testing. Conclusions: Published K‐index cutoffs vary due to different settings of CSF KFLC results below LOD. Using a reflex approach, where samples within a certain K‐index gray area are subjected to OCB verification testing, and where samples with CSF KFLC below LOD are considered negative, was the most efficient laboratory algorithm. K‐index may also have prognostic value in MS.
- Open Access
- 9 December 2024
- Published by Elsevier in Clinica Chimica Acta
- Vol. 567, 120086
Artificial intelligence aided serum protein electrophoresis analysis of Finnish patient samples: Retrospective validation
- 9 December 2024
- Published by Elsevier in Clinica Chimica Acta
- Vol. 567, 120086
Open AccessArtificial intelligence aided serum protein electrophoresis analysis of Finnish patient samples: Retrospective validation
- 10 May 2024
- Published by Elsevier in Clinica Chimica Acta
- Vol. 559, 119720
Corrigendum to “The European biological variation study (EuBIVAS): Biological variation data for testosterone, follicle stimulating hormone, prolactin, luteinizing hormone and dehydroepiandrosterone sulfate in men” [Clin. Chim. Acta 555 (2024) 117806]
- 10 May 2024
- Published by Elsevier in Clinica Chimica Acta
- Vol. 559, 119720
Corrigendum to “The European biological variation study (EuBIVAS): Biological variation data for testosterone, follicle stimulating hormone, prolactin, luteinizing hormone and dehydroepiandrosterone sulfate in men” [Clin. Chim. Acta 555 (2024) 117806]
- Open Access
- 9 February 2024
- Published by Elsevier in Clinica Chimica Acta
- Vol. 555, 117806
The European biological variation study (EuBIVAS): Biological variation data for testosterone, follicle stimulating hormone, prolactin, luteinizing hormone and dehydroepiandrosterone sulfate in men
- 9 February 2024
- Published by Elsevier in Clinica Chimica Acta
- Vol. 555, 117806
Open AccessThe European biological variation study (EuBIVAS): Biological variation data for testosterone, follicle stimulating hormone, prolactin, luteinizing hormone and dehydroepiandrosterone sulfate in men
- Open Access
- 8 June 2021
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 5 (8) , bvab106
Comparison of Serum and Urinary 5-Hydroxyindoleacetic Acid as Biomarker for Neuroendocrine Neoplasms
Context Patients with serotonin-secreting neuroendocrine neoplasms (NENs) have increased serum 5-hydroxyindoleacetic acid (5HIAA) concentrations. Serum 5HIAA thus serves as a biomarker in NEN. Objective To evaluate an improved tandem mass spectrometric serum 5HIAA assay for diagnosis and follow-up of NEN in a clinical cohort. Design A retrospective study during 2016-2018 at the Diagnostic Center and Department of Endocrinology at Helsinki University Hospital, Finland. Methods Detailed patient data was obtained from 116 patients. Serum 5HIAA was analyzed by 2 different liquid chromatography with tandem mass spectrometry (LC-MS/MS) assays with samples prepared either by protein precipitation or solid phase extraction. Twenty-four–hour urine 5HIAA samples (n = 33) were analyzed by amperometric LC, and the results were compared. Specificity and sensitivity were calculated by receiver operating characteristic (ROC) analysis. Results We achieved 5 to10 000 nmol/L linearity and ≤2.5% variation with our new serum 5HIAA assay. In ROC analysis, the area under curve was 85% by serum assays [upper reference limit (URL) value 123 nmol/L] and 88% by the 24-h urine 5HIAA assay (URL value of 47.1 µmol), respectively. A difference (P < 0.001) between patients with active NEN and patients in remission was found by all 5HIAA assays. Conclusion Serum 5HIAA by LC-MS/MS after protein precipitation performs equally well for the diagnosis of NEN as urinary 5HIAA LC assay. The outcome and sensitivity for serum and 24-h urine assays are convergent. Due to much more reliable and convenient sampling, we recommend serum instead of 24-h urine 5HIAA for diagnosis and follow-up of NEN patients.
- 8 June 2021
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 5 (8) , bvab106
Open AccessComparison of Serum and Urinary 5-Hydroxyindoleacetic Acid as Biomarker for Neuroendocrine Neoplasms
Context Patients with serotonin-secreting neuroendocrine neoplasms (NENs) have increased serum 5-hydroxyindoleacetic acid (5HIAA) concentrations. Serum 5HIAA thus serves as a biomarker in NEN. Objective To evaluate an improved tandem mass spectrometric serum 5HIAA assay for diagnosis and follow-up of NEN in a clinical cohort. Design A retrospective study during 2016-2018 at the Diagnostic Center and Department of Endocrinology at Helsinki University Hospital, Finland. Methods Detailed patient data was obtained from 116 patients. Serum 5HIAA was analyzed by 2 different liquid chromatography with tandem mass spectrometry (LC-MS/MS) assays with samples prepared either by protein precipitation or solid phase extraction. Twenty-four–hour urine 5HIAA samples (n = 33) were analyzed by amperometric LC, and the results were compared. Specificity and sensitivity were calculated by receiver operating characteristic (ROC) analysis. Results We achieved 5 to10 000 nmol/L linearity and ≤2.5% variation with our new serum 5HIAA assay. In ROC analysis, the area under curve was 85% by serum assays [upper reference limit (URL) value 123 nmol/L] and 88% by the 24-h urine 5HIAA assay (URL value of 47.1 µmol), respectively. A difference (P < 0.001) between patients with active NEN and patients in remission was found by all 5HIAA assays. Conclusion Serum 5HIAA by LC-MS/MS after protein precipitation performs equally well for the diagnosis of NEN as urinary 5HIAA LC assay. The outcome and sensitivity for serum and 24-h urine assays are convergent. Due to much more reliable and convenient sampling, we recommend serum instead of 24-h urine 5HIAA for diagnosis and follow-up of NEN patients.
- 6 January 2015
- Published by Springer Nature
- Vol. 1264, 271-278
Mitochondrial Coenzyme Q10 Determination via Isotope Dilution Liquid Chromatography Tandem Mass Spectrometry
Coenzyme Q10 (CoQ10) is an essential part of the mitochondrial respiratory chain. Here, we describe an accurate and sensitive liquid chromatography tandem mass spectrometry (LC-MS/MS) method for determination of mitochondrial CoQ10 in isolated mitochondria. In the assay, mitochondrial suspensions are spiked with CoQ10-[2H6] internal standard, extracted with organic solvents, and CoQ10 quantified by LC-MS/MS using multiple reaction monitoring (MRM).
- 6 January 2015
- Published by Springer Nature
- Vol. 1264, 271-278
Mitochondrial Coenzyme Q10 Determination via Isotope Dilution Liquid Chromatography Tandem Mass Spectrometry
Coenzyme Q10 (CoQ10) is an essential part of the mitochondrial respiratory chain. Here, we describe an accurate and sensitive liquid chromatography tandem mass spectrometry (LC-MS/MS) method for determination of mitochondrial CoQ10 in isolated mitochondria. In the assay, mitochondrial suspensions are spiked with CoQ10-[2H6] internal standard, extracted with organic solvents, and CoQ10 quantified by LC-MS/MS using multiple reaction monitoring (MRM).
- 1 August 2013
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 59 (8) , 1260-1267
Mitochondrial Coenzyme Q10 Determination by Isotope-Dilution Liquid Chromatography–Tandem Mass Spectrometry
BACKGROUND: Coenzyme Q10 (CoQ10) is an essential part of the mitochondrial respiratory chain. Unlike most other respiratory chain disorders, CoQ10 deficiency is potentially treatable. We aimed to develop and validate an accurate liquid chromatography–tandem mass spectrometry (LC-MS/MS) method for the determination of mitochondrial CoQ10 in clinical samples. METHODS: We used mitochondria isolated from muscle biopsies of patients (n = 166) suspected to have oxidative phosphorylation deficiency. We also used fibroblast mitochondria from 1 patient with CoQ10 deficiency and 3 healthy individuals. Samples were spiked with nonphysiologic CoQ10-[2H6] internal standard, extracted with 1-propanol and with ethanol and hexane (2 mL/5 mL), and CoQ10 quantified by LC-MS/MS. The method and sample stability were validated. A reference interval was established from the patient data. RESULTS: The method had a limit of quantification of 0.5 nmol/L. The assay range was 0.5–1000 nmol/L and the CVs were 7.5%–8.2%. CoQ10 was stable in concentrated mitochondrial suspensions. In isolated mitochondria, the mean ratio of CoQ10 to citrate synthase (CS) activity (CoQ10/CS) was 1.7 nmol/U (95% CI, 1.6–1.7 nmol/U). We suggest a CoQ10/CS reference interval of 1.1–2.8 nmol/U for both sexes and all ages. The CoQ10/CS ratio was 5-fold decreased in fibroblast mitochondria from a patient with known CoQ10 deficiency due to recessive prenyl (decaprenyl) diphosphate synthase, subunit 2 (PDSS2) mutations. CONCLUSIONS: Normalization of mitochondrial CoQ10 concentration against citrate synthase activity is likely to reflect most accurately the CoQ10 content available for the respiratory chain. Our assay and the established reference range should facilitate the diagnosis of respiratory chain disorders and treatment of patients with CoQ10 deficiency.
- 1 August 2013
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 59 (8) , 1260-1267
Mitochondrial Coenzyme Q10 Determination by Isotope-Dilution Liquid Chromatography–Tandem Mass Spectrometry
BACKGROUND: Coenzyme Q10 (CoQ10) is an essential part of the mitochondrial respiratory chain. Unlike most other respiratory chain disorders, CoQ10 deficiency is potentially treatable. We aimed to develop and validate an accurate liquid chromatography–tandem mass spectrometry (LC-MS/MS) method for the determination of mitochondrial CoQ10 in clinical samples. METHODS: We used mitochondria isolated from muscle biopsies of patients (n = 166) suspected to have oxidative phosphorylation deficiency. We also used fibroblast mitochondria from 1 patient with CoQ10 deficiency and 3 healthy individuals. Samples were spiked with nonphysiologic CoQ10-[2H6] internal standard, extracted with 1-propanol and with ethanol and hexane (2 mL/5 mL), and CoQ10 quantified by LC-MS/MS. The method and sample stability were validated. A reference interval was established from the patient data. RESULTS: The method had a limit of quantification of 0.5 nmol/L. The assay range was 0.5–1000 nmol/L and the CVs were 7.5%–8.2%. CoQ10 was stable in concentrated mitochondrial suspensions. In isolated mitochondria, the mean ratio of CoQ10 to citrate synthase (CS) activity (CoQ10/CS) was 1.7 nmol/U (95% CI, 1.6–1.7 nmol/U). We suggest a CoQ10/CS reference interval of 1.1–2.8 nmol/U for both sexes and all ages. The CoQ10/CS ratio was 5-fold decreased in fibroblast mitochondria from a patient with known CoQ10 deficiency due to recessive prenyl (decaprenyl) diphosphate synthase, subunit 2 (PDSS2) mutations. CONCLUSIONS: Normalization of mitochondrial CoQ10 concentration against citrate synthase activity is likely to reflect most accurately the CoQ10 content available for the respiratory chain. Our assay and the established reference range should facilitate the diagnosis of respiratory chain disorders and treatment of patients with CoQ10 deficiency.
- Open Access
- 1 August 2013
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 59 (8) , 1271-1273
Comparison of Bleomycin-Detectable Iron and Labile Plasma Iron Assays
- 1 August 2013
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 59 (8) , 1271-1273
Open AccessComparison of Bleomycin-Detectable Iron and Labile Plasma Iron Assays